According to the FDA’s requirements, the effectiveness of the vaccine should be at least 50%.
Moderna said it plans to report the first results of a late-stage trial of its experimental coronavirus vaccine later this month and may apply for US registration in December.
On Monday, hopes for an effective vaccine were bolstered when Pfizer announced that its vaccine showed 90 percent effectiveness based on interim results from large-scale clinical trials.
After Moderna provides interim data on the vaccine’s effectiveness, the company may have to wait for additional data on the absence of side effects for two months before applying to regulatory authorities. Security data is expected in the second half of November.
According to Moderna CEO Stephane Bancel, according to the Food and drug administration requirements, the effectiveness of the vaccine must be at least 50 percent. The company does not yet know how effective its experimental vaccine is.
“It’s difficult to predict performance until there is data,” said Bancel, speaking at a conference at Credit Suisse.